{
  "guideline": {
    "id": "PA166104852",
    "name": "Annotation of FDA Label for citalopram and CYP2C19",
    "source": "FDA",
    "version": 40,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104852",
    "relatedChemicals": [
      {
        "id": "PA449015",
        "name": "citalopram",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166308322",
      "name": "Recommendation Annotation PA166308322",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449015",
          "name": "citalopram",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452193821,
        "html": "<p>&quot;Celexa [citalopram] 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "CYP2C19 poor metabolizers have higher systemic concentration and adverse reaction risk (QT prolongation)."
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166308342",
      "name": "Recommendation Annotation PA166308342",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449015",
          "name": "citalopram",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452193841,
        "html": "<p>&quot;Celexa [citalopram] 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "CYP2C19 poor metabolizers have higher systemic concentration and adverse reaction risk (QT prolongation)."
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Celexa (citalopram), NDA020822, Allergan, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020822"
    }
  ],
  "version": "2024-02-29-20-19"
}